These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34298840)

  • 1. Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index.
    Nilsson JN; Siikanen J; Hedman C; Juhlin CC; Ihre Lundgren C
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer.
    Nilsson JN; Grybäck P; Juhlin CC; Hedman C; Lundgren CI
    Endocrine; 2023 Nov; 82(2):343-352. PubMed ID: 37284971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.
    Nilsson JN; Siikanen J; Condello V; Jatta K; Saini R; Hedman C; Ihre Lundgren C; Juhlin CC
    Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37352166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 5. Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators.
    Qiu ZL; Shen CT; Sun ZK; Song HJ; Zhang GQ; Luo QY
    Front Endocrinol (Lausanne); 2019; 10():903. PubMed ID: 31998236
    [No Abstract]   [Full Text] [Related]  

  • 6. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results.
    Dobrenic M; Huic D; Zuvic M; Grosev D; Petrovic R; Samardzic T
    Radiol Oncol; 2011 Sep; 45(3):189-95. PubMed ID: 22933955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
    Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH
    Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unstimulated Serum Thyroglobulin Levels after Thyroidectomy and Radioiodine Therapy for Intermediate-Risk Thyroid Cancer Are Not Always a Reliable Marker of Lymph Node Recurrence: Case Report and a Lesson for Clinicians.
    Foppiani L; Sola S; Cabria M; Bottoni G; Piccardo A
    Case Rep Endocrinol; 2020; 2020():8827503. PubMed ID: 33101736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009.
    Ceresini G; Corcione L; Michiara M; Sgargi P; Teresi G; Gilli A; Usberti E; Silini E; Ceda GP
    Cancer; 2012 Nov; 118(22):5473-80. PubMed ID: 22517468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
    Mishra A; Pal L; Mishra SK
    World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan.
    Ansari M; Babaei AA; Shafiei B; Javadi H; Assadi M; Nabipour I; Asli IN
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1925-9. PubMed ID: 25010624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.
    Simon D; Körber C; Krausch M; Segering J; Groth P; Görges R; Grünwald F; Müller-Gärtner HW; Schmutzler C; Köhrle J; Röher HD; Reiners C
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):775-82. PubMed ID: 12029551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
    Schaap J; Eustatia-Rutten CF; Stokkel M; Links TP; Diamant M; van der Velde EA; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):117-24. PubMed ID: 12100079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.